68Gallium-labelled FAP-inhibitors outperforms 18F-fluorodeoxyglucose PET/CT for recurrent ovarian cancer in the poly adenosine diphosphate-ribose polymerase inhibitor era - PubMed
12 hours ago
- #PARPi Resistance
- #Ovarian Cancer
- #PET/CT Imaging
- 68Ga-FAPI shows superior lesion detection and diagnostic accuracy compared to 18F-FDG PET/CT for recurrent ovarian cancer.
- Patients under PARPi maintenance therapy are more likely to have additional FAPI-positive lesions, indicating potential resistance mechanisms.
- Hypoglycolysis and cancer-associated fibroblast (CAF) activation are identified as underlying mechanisms for PARPi resistance in FAPI+/FDG- lesions.
- The study included 89 patients with platinum-sensitive high-grade serous ovarian cancer, showing 96.3% diagnostic accuracy for FAPI vs. 86.9% for FDG.
- Patients with additional FAPI-detected lesions had shorter progression-free survival, especially those previously on PARPi maintenance therapy.